Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News enVVeno Medical Corp NVNO

Healthcare Medical Devices
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system... see more

Recent & Breaking News (NDAQ:NVNO)

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Accesswire 2 days ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Accesswire 3 days ago

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

Accesswire October 31, 2024

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

Accesswire October 28, 2024

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Accesswire September 26, 2024

enVVeno Medical Corporation Announces Proposed Public Offering

Accesswire September 26, 2024

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

Accesswire September 3, 2024

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Accesswire August 14, 2024

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Accesswire August 1, 2024

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Accesswire June 25, 2024

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

Accesswire June 21, 2024

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

Accesswire June 17, 2024

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

Accesswire May 8, 2024

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

Accesswire April 24, 2024

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

Accesswire April 16, 2024

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

Accesswire April 9, 2024

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity

Accesswire March 15, 2024

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

Accesswire March 6, 2024

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Accesswire February 29, 2024

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024

Accesswire February 20, 2024